Newsweek highlights an article authored by research associate by Jason Karlawish which gives his opinion on Biogen's experimental drug, aducanumab, which may clear amyloid plaque from the brain, but according to him the company hasn't made a convincing case that it slows the progression of Alzheimer's disease.
Citations:
“New Alzheimer’s Drug Brings Hope—And Tough Choices for Patients, Caregivers.” Newsweek, M Gunn, December 21, 2022.
"If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it" STAT, Jason Karlawish, May 30, 2021.